Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

AMS vs GRAL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

GRAL Captures Overall Composite Edge (54.5 HOLD vs 33.8 SELL), While AMS Leads 4–2 on Growth & Valuation Pillars

GRAL Overall Winner 6-Pillar Tally: AMS 4 – 2 GRAL Matrix Metrics: AMS 5 – 5 GRAL

As of Nov 16, 2026, GRAIL, Inc. (GRAL) captures the overall head-to-head institutional edge over American Shared Hospital Services (AMS) on higher Unified Composite conviction (54.5/100 HOLD vs. 33.8/100 SELL) after splitting the core matrix 5–5 (led by Valuation Multiples, Growth & Scale), while AMS wins 4–2 across the 6-pillar growth and valuation breakdown. AMS trades at $1.07 (44.6x Forward P/E, -7.4% operating margin) versus GRAL at $105.60 (1.1x Forward P/E, -332.0% operating margin).

  • Growth vs. Quality Trade-Off: GRAL earns the overall head-to-head edge with a stronger Unified Composite Score (54.5/100 HOLD vs. AMS 33.8/100 SELL) and 3.09β · 99% Vol risk profile, whereas AMS leads top-line expansion (+19.2% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: AMS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 27.1); meanwhile GRAL is in a Breakdown options structure phase (RSI 37.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AMS vs GRAL
AMS NYSE American
American Shared Hospital Services
Services-Medical Laboratories
$1.07
-0.93% 1D
Market Cap $7.2M
TTM Revenue $30M
Forward P/E 44.6x
Beta / 30D Vol 0.18β · 46% Vol
Unified Composite Score
33.8 / 100 SELL
Tech 24.0 Fund 38.0 Flow 50.0 Mom 30.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.9%), weak momentum, RSI 27
RSI-14: 27.1 · SMA20: $1.21 · SMA50: $1.32
GRAL NASDAQ Head-to-Head Winner
GRAIL, Inc. Common Stock
Services-Medical Laboratories
$105.60
-8.88% 1D
Market Cap $5.2B
TTM Revenue $167M
Forward P/E 1.1x
Beta / 30D Vol 3.09β · 99% Vol
Unified Composite Score
54.5 / 100 HOLD
Tech 35.0 Fund 49.0 Flow 57.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 38
RSI-14: 37.7 · SMA20: $132.32 · SMA50: $121.37

6-Pillar Scorecard Institutional Category Breakdown (AMS 4 – 2 GRAL)

Columns: Metric · AMS · GRAL
1. Valuation Multiples GRAL
Forward P/E 44.6x 1.1x
Trailing P/E 44.6x 1.1x
PEG Ratio N/M N/M
EV / Revenue 0.8x 31.6x
2. Growth & Scale GRAL
Revenue Growth (YoY) +19.2% +3.7%
Earnings Growth (YoY) -38.1% +0.0%
TTM Revenue (USD) $30M $167M
Market Cap $7.2M $5.2B
3. Profitability & Quality AMS
Gross Margin 34.8% 46.7%
Operating Margin -7.4% -332.0%
Net Profit Margin -5.8% -243.8%
Return on Equity (ROE) -12.1% -17.3%
4. Balance Sheet & Cash Flow AMS
Cash Generation (TTM) -$916,000 -$312M
Cash Flow Margin -3.0% N/A
Net Cash / Leverage $17M Net Debt (0.95x D/E) $57M Net Debt (0.03x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AMS
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 93.0% (53rd %ile)
Put/Call OI Skew N/A 0.81x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat AMS
OpEx & R&D Intensity 42.2% of Rev ($13M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Care Facilities Operator Diagnostics & Research Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AMS (5) vs GRAL (5)
Institutional Metric AMS GRAL Criterion Row Edge
Market Capitalization
Scale
$7.2M $5.2B Larger Scale GRAL
Trailing P/E Ratio
Valuation
44.6x 1.1x Lower Multiple GRAL
Forward P/E Ratio
Valuation
44.6x 1.1x Lower Multiple GRAL
Revenue Growth (YoY)
Growth
+19.2% +3.7% Higher Growth AMS
Operating Margin (TTM)
Profitability
-7.4% -332.0% Higher Margin AMS
Net Profit Margin
Profitability
-5.8% -243.8% Higher Margin AMS
Return on Equity (ROE)
Capital Efficiency
-12.1% -17.3% Higher ROE AMS
52-Week Range Position
Momentum
6% ($1–$2) 51% ($42–$166) Stronger Trend GRAL
Beta / 30D Volatility
Risk Regime
0.18β · 46% Vol 3.09β · 99% Vol Lower Realized Risk AMS
Unified Institutional Score
Composite Signal
33.8 / 100 (SELL) 54.5 / 100 (HOLD) Higher Composite GRAL
Trailing 12M Revenue (USD)
Operating Scale
$30M $167M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
34.8% 46.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.8x EV/Rev N/M PEG · 31.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$916,000 ($17M Net Debt (0.95x D/E)) -$312M ($57M Net Debt (0.03x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon GRAL +6.05 pp
AMS: -16.41% · GRAL: -10.36%
3M Horizon GRAL +81.93 pp
AMS: -30.97% · GRAL: +50.96%
6M Horizon GRAL +104.24 pp
AMS: -27.21% · GRAL: +77.03%
1Y Horizon GRAL +79.15 pp
AMS: -52.23% · GRAL: +26.92%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period AMS Revenue GRAL Revenue AMS Op. Margin GRAL Op. Margin Margin Leader
FY2018 $20M N/A 9.4% N/A AMS
FY2019 $20M N/A 7.5% N/A AMS
FY2020 $20M N/A -53.1% N/A AMS
FY2021 $20M N/A 7.7% N/A AMS
FY2022 $20M N/A 12.3% N/A AMS
FY2023 $20M $90M 1.3% -1627.6% AMS
FY2024 $30M $130M -9.9% -1743.0% AMS
FY2025 $30M $150M -12.8% -382.0% AMS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AMS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AMS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
GRAL BREAKDOWN
12d in phase · OBV DISTRIBUTION
Current IV 93.0%
IV Percentile 53rd %ile
Put/Call OI Skew 0.81x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact GRAL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AMS Moat Profile Cyclical / Execution-Driven Positioning
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $7.2M market capitalization and -7.4% operating margin.
OpEx & R&D Reinvestment 42.2% of Rev ($13M)
90D Engineering Disclosures 0 Published
Mapped Supply-Chain Ecosystem (18 partners):
Taiwan Semiconductor Manufacturing Company GlobalFoundries ASE Technology Holding Amkor Technology
GRAL Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $5.2B market capitalization and -332.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AMS vs GRAL Key Questions & Quantitative Answers

As of Nov 16, 2026, GRAIL, Inc. (GRAL) captures the overall head-to-head institutional edge over American Shared Hospital Services (AMS) on higher Unified Composite conviction (54.5/100 HOLD vs. 33.8/100 SELL) after splitting the core matrix 5–5 (led by Valuation Multiples, Growth & Scale), while AMS wins 4–2 across the 6-pillar growth and valuation breakdown. AMS trades at $1.07 (44.6x Forward P/E, -7.4% operating margin) versus GRAL at $105.60 (1.1x Forward P/E, -332.0% operating margin). Growth vs. Quality Trade-Off: GRAL earns the overall head-to-head edge with a stronger Unified Composite Score (54.5/100 HOLD vs. AMS 33.8/100 SELL) and 3.09β · 99% Vol risk profile, whereas AMS leads top-line expansion (+19.2% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: AMS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 27.1); meanwhile GRAL is in a Breakdown options structure phase (RSI 37.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

GRAL leads the Growth & Scale pillar: AMS posts +19.2% YoY revenue growth and -38.1% YoY earnings growth on $30M TTM revenue (34.8% gross margin, -7.4% operating margin), compared with GRAL at +3.7% YoY revenue growth and +0.0% YoY earnings growth on $167M TTM revenue (46.7% gross margin, -332.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), AMS cumulative revenue shifted +50.0% while GRAL shifted +66.7%. In operating R&D and SG&A reinvestment, AMS deploys 42.2% of Rev ($13M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for GRAL.

GRAL screens cheaper on headline valuation multiples. AMS trades at 44.6x Forward P/E, 44.6x Trailing P/E, N/M PEG, and 0.8x EV/Revenue (-3.0% FCF margin), whereas GRAL trades at 1.1x Forward P/E, 1.1x Trailing P/E, N/M PEG, and 31.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AMS (-12.1% ROE) versus GRAL (-17.3% ROE) capital efficiency.

In options market volatility and institutional positioning, AMS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.18β · 46% Vol realized risk). By comparison, GRAL carries 93.0% implied volatility (53rd %ile, Balanced (25th–60th %ile)), a 0.81x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (3.09β · 99% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.